Health Discovery Corporation

Health Discovery Corporation (HDC) is a medical diagnostic company based out of Savannah, Georgia. They are focused on using Support vector machines (SVMs) to identify cancer based proteins. (OTCBB: HDVY) is a United States corporation which is focused on identifying proteins using SVM-RFE technologies. The company has operations in the United States in California, New York and Georgia.

Assets

Health Discovery Corporation (HDC) has the only issued patents in the world for the SVM-RFE technology , which was discovered by the HDC science team. The SVM-RFE technology was the method used to discover the Company's new tissue and urine based prostate cancer tests recently licensed to Quest Diagnostics (NYSE: DGX ), Abbott Laboratories (NYSE: ABT ) and Clarient Inc. (Nasdaq: CLRT ).

Health Discovery Corporation (HDC)is currently developing new molecular diagnostic tests for the early detection of pancreatic cancer.

Products

2/16/10- Health Discovery Corporation announced a mobile application for melanoma/skin cancer. The application will let users take a picture of a mole, lesion or birthmark on their bodies using their mobile phones. They will then be able to send the image to Health Discovery Corporation, and immediately receive a risk assessment on there phone for melanoma and other skin cancers.

Has licensed a Urine-based prostate cancer test for development and commercialization to Quest Diagnostics (NYSE: DGX) and Abbott (NYSE: ABT) on a royalty-based, world-wide co-exclusive basis.

Patents

HDC has a total of 71 patents pending and issued. HDC now holds exclusive rights to a total of 37 issued U.S. and foreign patents. There will be 41 when the 4 new ones (subjects of the Notices of Allowance) issue in the next few months. HDC has a total of 71 patents pending and issued for various SRM-RFE technologies.

Facts

HDC's patents played a major role in identifying the biomarkers the recently FDA-approved ovarian cancer (ova1)test developed by Vermillion, Inc.

“In addition to our own biomarker discovery programs, we are continuing to pursue revenue-producing licensing opportunities, retroactively, as in the case of Vermillion, and going forward, to develop new applications of the technology within our intellectual property portfolio.” 

Key license partners include Abbott Laboratories (NYSE: ABT), Quest Diagnostics (NYSE: DGX), Clarient Inc. (Nasdaq: CLRT) and Pfizer Inc.